KF
EBS icon

Krilogy Financial’s Emergent Biosolutions EBS Stock Holding History

Krilogy Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$8K – 782
2017
Q3 		$8K Hold
200
– – ﹤0.01% 599
2017
Q2 		$7K Buy
200
+50
+33% +$1.54K ﹤0.01% 563
2017
Q1 		$5K Hold
150
– – ﹤0.01% 574
2016
Q4 		$5K Hold
150
– – ﹤0.01% 574
2016
Q3 		$5K Buy
150
+50
+50% +$1.45K ﹤0.01% 592
2016
Q2 		$3K Buy
+100
New +$3.92K ﹤0.01% 648

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Krilogy Financial's EBS Position: Q4 2017 in Review

Krilogy Financial sold out of Emergent Biosolutions (EBS) in Q4 2017, closing a stake of 200 shares — an estimated $8K sold.

Krilogy Financial first reported a position in EBS in Q2 2016 and held it in 6 quarters. The position peaked at $8K in Q3 2017. 238 funds tracked by Wall St. Rank hold EBS as of Q4 2017.

  • Krilogy Financial reported no remaining Emergent Biosolutions position as of Q4 2017 after selling out during the quarter.
  • Krilogy Financial sold 200 Emergent Biosolutions shares in Q4 2017, an estimated $8K.
  • Krilogy Financial first reported a position in Emergent Biosolutions in Q2 2016 and held it in 6 quarters.
  • Krilogy Financial's Emergent Biosolutions position peaked at $8K in Q3 2017.
  • 238 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2017.

Based on Krilogy Financial's 13F filing for Q4 2017, filed 14 Feb 2018.